Interleukin 2 and HIV RNA levels [4]

Archives of Internal Medicine

Volumn 167, Issue 19, 2007, Pages 2144-2145

  Go, Roderick ^a   Steigbigel, Roy ^b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INTERLEUKIN 2; NUCLEOTIDE; RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LETTER; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RNA REPLICATION; UNSPECIFIED SIDE EFFECT;

EID: 35748958093     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.19.2144-b     Document Type: Letter

References (4)

1. Mitsuyasu R, Gelman R, Cheng DW, et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection. Arch Intern Med. 2007;167(6):597-605.
2. Kuritzkes DR, Ribaudo HJ, Squires KE, et al. Plasma HIV-1 RNA dynamics in antiretroviral-naïve subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis. 2007;195(8):1169-1176.
3. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850-1861.
4. Markowitz M, Perelson AS. Window of opportunity. J Infect Dis. 2007;195(8):1087-1088.